Status:

RECRUITING

Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds

Lead Sponsor:

Icahn School of Medicine at Mount Sinai

Conditions:

Wound Healing

Mohs Micrographic Surgery

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

Topical timolol, a β2-Adrenergic receptor (B2AR) antagonist, has demonstrated promise in wound healing over the past several years. The majority of the literature has evaluated the use of topical timo...

Eligibility Criteria

Inclusion

  • Be scheduled to undergo MMS at 234 East 85th St for a skin cancer that is deemed Mohs
  • Appropriate by the Mohs surgery appropriate use criteria
  • Have an open surgical wound \< 4 cm and \> 0.5 cm
  • Be ≥18 years of age
  • English-speaking
  • Provide a signed and dated informed consent form
  • State willingness to comply with all study procedures

Exclusion

  • Age less than 18 years of age
  • Open surgical wound \> 4 cm
  • If tumor clearance cannot be achieved with MMS
  • Pregnant women
  • Breastfeeding women
  • Patients who are taking oral beta-blockers (ie oral timolol, metoprolol, carvedilol, propranolol, atenolol)
  • Patients who are currently taking any of the following medications: clonidine, digoxin, methyldopa, quinidine, fluoxetine and paroxetine, bupropion
  • Patient currently taking a calcium channel blocker AND has pre-existing heart failure as defined by a reduced ejection fraction
  • Patients with pre-existing hypotension
  • Pre-existing diagnosis of sinus bradycardia
  • Pre-existing diagnosis of second or third degree atrioventricular block
  • Congestive heart failure
  • Pre-existing diagnosis of severe asthma
  • Pre-existing diagnosis of chronic obstructive pulmonary disease
  • Any known hypersensitivity to 0.5% timolol solution
  • Patients who have a wound where primary closure is feasible and desired by the patient
  • Defect size \<0.5 cm
  • Prior sensitivity or known allergy to timolol

Key Trial Info

Start Date :

January 3 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2026

Estimated Enrollment :

102 Patients enrolled

Trial Details

Trial ID

NCT06941467

Start Date

January 3 2025

End Date

April 1 2026

Last Update

April 23 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mount Sinai

New York, New York, United States, 10028